MLchartDataset catalogue

autologous CMV-pp65-flLAMP mRNA-loaded dendritic cell vaccine

Term · Oncology and biomedicine · MLC-T-ONC-011576

A cancer cell vaccine consisting of autologous dendritic cells (DCs) loaded with mRNA encoding the human cytomegalovirus (CMV) matrix protein pp65 (65 kDa lower matrix phosphoprotein; UL83) as a fusion protein with the full-length lysosome-associated membrane protein (flLAMP), with potential immunostimulatory and antineoplastic activities. Upon vaccination, the autologous CMV-pp65-flLAMP mRNA loaded DC vaccine exposes the immune system to the CMV pp65 peptide, which may elicit a cytotoxic T-lymphocyte (CTL) response against CMV pp65-expressing tumor cells. The incorporation of flLAMP may route CMV pp-65 antigens into the lysosomal compartment, resulting in enhanced MHC class II antigen presentation, thereby promoting CD4-positive T-cell responses. The CMV pp65 protein is the primary component of the enveloped subviral particle of CMV and is expressed in certain tumor types.

Table 1. Record
IdentifierMLC-T-ONC-011576
FieldOncology and biomedicine
Synonymsautologous pp65-flLAMP DC vaccine; autologous CMV-pp65-flLamp DCs; autologous pp65-flLAMP DCs; autologous flLAMP-pp65-DC vaccine; autologous flLAMP-pp65-DCs; autologous CMV pp65-LAMP mRNA-loaded DC vaccine; autologous flLAMP-pp65 mRNA-pulsed DC vaccine
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-011576",
  "term": "autologous CMV-pp65-flLAMP mRNA-loaded dendritic cell vaccine",
  "field": "Oncology and biomedicine",
  "definition": "A cancer cell vaccine consisting of autologous dendritic cells (DCs) loaded with mRNA encoding the human cytomegalovirus (CMV) matrix protein pp65 (65 kDa lower matrix phosphoprotein; UL83) as a fusion protein with the full-length lysosome-associated membrane protein (flLAMP), with potential immunostimulatory and antineoplastic activities. Upon vaccination, the autologous CMV-pp65-flLAMP mRNA loaded DC vaccine exposes the immune system to the CMV pp65 peptide, which may elicit a cytotoxic T-lymphocyte (CTL) response against CMV pp65-expressing tumor cells. The incorporation of flLAMP may route CMV pp-65 antigens into the lysosomal compartment, resulting in enhanced MHC class II antigen presentation, thereby promoting CD4-positive T-cell responses. The CMV pp65 protein is the primary component of the enveloped subviral particle of CMV and is expressed in certain tumor types.",
  "synonyms": [
    "autologous pp65-flLAMP DC vaccine",
    "autologous CMV-pp65-flLamp DCs",
    "autologous pp65-flLAMP DCs",
    "autologous flLAMP-pp65-DC vaccine",
    "autologous flLAMP-pp65-DCs",
    "autologous CMV pp65-LAMP mRNA-loaded DC vaccine",
    "autologous flLAMP-pp65 mRNA-pulsed DC vaccine"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/autologous-cmv-pp65-fllamp-mrna-loaded-dendritic-cell-vaccine/"
}

Record 2,910 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.